Evidence map›Paper›PMID 42012531›Full record

ArticleJournal of cancer research and clinical oncology2026

Treatment of retroperitoneal sarcoma in Germany between 2000 and 2022: a retrospective analysis from the German Cancer Registry Group.

Nikola Beck, Frank Goßmann, Peter Hohenberger, Bernd Kasper, Franka Menge, Christoph K W Deinzer, Bianca Franke, Anne Hendricks, Monika Klinkhammer-Schalke, Katharina Rausch and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nikola BeckRegional Centre Würzburg, Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, Grombühlstraße 52, 97080, Würzburg, Germany.ORCID http://orcid.org/0009-0002-6635-6520
Frank GoßmannRegional Centre Würzburg, Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, Grombühlstraße 52, 97080, Würzburg, Germany.ORCID http://orcid.org/0009-0008-1154-3314
Peter HohenbergerDivision of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0001-5359-5923
Bernd KasperSarcoma Unit, Department of Surgery, Medical Faculty, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0001-8425-8356
Franka MengeDivision of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany.
Christoph K W DeinzerDepartment of Internal Medicine VIII - Medical Oncology and Pneumology, Medical University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0009-0006-1961-9382
Bianca FrankeAssociation of German Tumor Centers, ADT, Berlin, Germany.
Anne HendricksSarcoma Center Würzburg, University Hospital of Würzburg, Würzburg, Germany.
Monika Klinkhammer-SchalkeAssociation of German Tumor Centers, ADT, Berlin, Germany.
Katharina RauschCancer Registry Saarland, Saarbrücken, Germany.
Fabian ReinwaldCancer Registry of Rhineland-Palatinate in the Institute for Digital Health Data RLP, Mainz, Germany.
Gabriele RobersInstitute for Community Medicine, Cancer Registry Mecklenburg-Western Pomerania, University Medicine Greifswald, 17487, Greifswald, Germany.ORCID http://orcid.org/0009-0008-0710-1791
Soo-Zin Kim-WannerHessian Cancer Registry, Hessian Office for Health and Care, Frankfurt am Main, Germany.
Constanze SchneiderClinical-Epidemiological Cancer Registry Brandenburg-Berlin, Cottbus, Germany.
Armin WiegeringClinic for General, Visceral, Transplantation and Thoracic Surgery, University Hospital Frankfurt, Frankfurt am Main, Germany.ORCID http://orcid.org/0000-0001-7777-0909
Manije Sabet-RashediGerman Cancer Society, Berlin, Germany.ORCID http://orcid.org/0009-0003-2644-243X
Sylke Ruth Zeissig *Regional Centre Würzburg, Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, Grombühlstraße 52, 97080, Würzburg, Germany. sylke.zeissig@lgl.bayern.de.ORCID http://orcid.org/0000-0002-0743-6128
Jens Jakob *Division of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0002-8499-7172

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study describes the treatment of retroperitoneal sarcoma (RPS) in Germany between 2000 and 2022, comparing it to existing recommendations and guidelines.

methodsData from the cancer registries of 13 out of 15 federal states was used. Included cases had a retroperitoneal localization (ICD) and histology (ICD-O) corresponding to soft tissue sarcoma. Descriptive analyses of treatment were conducted, focusing on surgical treatment including the development of local residual status and the number of organs resected.

resultsSurgery was the most common treatment for cases without metastases, being performed in 79% of cases with available grading data, while systemic therapy (7.6%) and radiotherapy (6.5%) were used less frequently; treatment information was missing for 17% of cases. The most frequent surgeries involved kidneys, intestines and the adrenal gland. In over a third of the cases (38%), multiple organs were resected, especially in cases of adipocytic tumors, where the rate was 46%.

conclusionGerman cancer registry data allow to characterize treatment of rare diseases such as RPS by supplying detailed information on tumor site and histology. Data quality of German cancer registries improved over time. Treatment patterns of RPS in Germany appear to follow current recommendations regarding extent of surgery and multimodal treatment. The findings align with existing cohort studies from expert centers and (inter-) national guidelines, emphasizing surgery as the only curative option, with multivisceral resection being the preferred approach, especially for adipocytic tumors. Despite potential limitations due to underreporting, cancer registry data provides valuable insights into the medical care situation of the rare RPS.

Indexed as

Retroperitoneal NeoplasmsSarcomaAdolescentAdultAgedAged, 80 and overFemaleGermanyHumansMaleMiddle AgedRegistriesRetrospective StudiesYoung AdultCancer registryOrgan resectionRetroperitoneal sarcomaSurgery

Identifiers

PMID42012531
PMCPMC13100076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.